Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III

 
• By Mandy Jackson
microscope
Pfizer's 20vPnC was non-inferior to its Prevnar 13 vaccine

More from Clinical Trials

More from R&D